KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Enterprise Value (2018 - 2025)

Adaptive Biotechnologies' Enterprise Value history spans 8 years, with the latest figure at -$220.8 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 0.78% year-over-year to -$220.8 million; the TTM value through Dec 2025 reached -$220.8 million, up 0.78%, while the annual FY2025 figure was -$220.8 million, 0.78% up from the prior year.
  • Enterprise Value for Q4 2025 was -$220.8 million at Adaptive Biotechnologies, down from -$213.0 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$193.6 million in Q1 2025 and bottomed at -$714.1 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$358.2 million (2021), against an average of -$365.1 million.
  • The largest annual shift saw Enterprise Value surged 50.3% in 2021 before it crashed 41.17% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$353.0 million in 2021, then plummeted by 41.17% to -$498.3 million in 2022, then skyrocketed by 30.45% to -$346.5 million in 2023, then skyrocketed by 35.79% to -$222.5 million in 2024, then rose by 0.78% to -$220.8 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Enterprise Value are -$220.8 million (Q4 2025), -$213.0 million (Q3 2025), and -$198.1 million (Q2 2025).